New heparin dosing for obese heart surgery patients may cut bleeding risk

NCT ID NCT02675647

Completed Disease control Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using ideal body weight (instead of total body weight) to calculate heparin doses during heart-lung bypass reduces excessive bleeding in obese patients. Sixty obese adults scheduled for heart surgery were randomly assigned to receive heparin based on either ideal or total body weight. Researchers measured heparin levels, clotting time, bleeding, and transfusion needs to see if the new dosing is safer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Heparin
What this could lead to: If successful, this could lead to safer heparin dosing guidelines for obese patients undergoing heart surgery, reducing bleeding risks.
What could go wrong: This is a small, single-center Phase 4 study with only 60 participants, so results may not apply broadly. The approach may not significantly reduce bleeding or complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC SURGERY CARDIOPULMONARY BYPASS OBESE PATIENTS (BMI ≥ 30 KG/M²)

Contacts and locations

Locations

Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.